Post-earnings recap
Reported
Tue, May 1, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Bio Rad Laboratories reported an EPS of $1.09, slightly missing expectations, which contributed to a modest stock increase of 0.15%. The lack of revenue data and guidance may leave investors cautious, but management's focus on growth and innovation could support future performance. Overall, the market reacted positively despite the EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.09 | N/A | -5.46% |
Overall, management remains cautiously optimistic about future performance. They emphasized their commitment to innovation and market expansion.
Management expressed confidence in long-term growth despite the EPS miss.
They highlighted ongoing investments in product development.